Shanghai Ruiliyuan Biotechnology Co., Ltd.

Quick facts

Phase 1 pipeline

• AFP Specific T Cell Receptor T Cells · Oncology
  Specific T Cell Receptor T Cells target the AFP antigen

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Shanghai Ruiliyuan Biotechnology Co., Ltd. portfolio CI brief
• Shanghai Ruiliyuan Biotechnology Co., Ltd. pipeline updates RSS

Related

• Sector hub: All tracked pharma companies